ONCAlert | 2018 Gastrointestinal Cancers Symposium

Lung Cancer MORE >>

Based on results from the phase III PACIFIC trial, durvalumab has been granted approval by the FDA for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.